1. Samumed’s Phase II efficacy resu

1. Samumed’s Phase II efficacy results. Samumed has probably had the smoothest development progress of any hair growth medication I’ve heard of. Samumed recently completed it’s Phase II trial for it’s topical hair growth product SM04554 in November 2015. Dr. Yazici, the Chief Medical Officer of Samumed, is quoted in their latest press release below.

“The Phase II safety and efficacy data so far are very promising and support moving this program into pivotal studies. We are analyzing the efficacy data further and plan to present results of both preclinical and clinical studies at upcoming medical conferences.”
The key points here are that the efficacy data is very promising, and promising enough to initiate the Phase III trial which will be the final trial to enable the commercialization of SM04554.
2. Shiseido’s trial for approval in Japan. By the end of January I anticipate that Shiseido will have commenced it’s first trial in Japan for the use of RCH-01 for hair growth. RCH-01 is the name of the technology which has been developed by Replicel using a person’s own cultured dermal papillae cells. Lee Buckler of Replicel has announced that Shiseido will be initiating their trial very soon. We also know that when all goes with the Shiseido’s first trial of RCH-01 in Japan, they will be able to offer the treatment to the public while they are completing later stage trials for RCH-01. That means anyone in the world can book a flight to Japan and get some hair growth injections. Yoohoo.
3. Histogen announcing trial in Mexico. We don’t know for sure yet if Mexico will be the official first destination for Histogen’s HSC. If it is though, that’d be cool, because Mexico is a lot closer to me than Japan or Turkey. We know that Gail Naughton of Histogen has been evaluating the best location to initiate the final study for the approval of HSC. We will know that location this year, and hopefully very soon.
4. Follicum Phase I trial. One of my favorite treatments in development right now, Follicum’s FOL-S-005, will begin it’s first trial for hair growth in the 1st quarter 2016. Follicum’s product is a topical peptide gel, and has shown pretty remarkable results in pre-clinical animal models. It’s my opinion that Follicum has been sort of “slept on” so far online, I believe that is going to change this year. The trials will take place in Berlin, Germany. Follicum has previously said that it would announce recruitment availability for the trial.
5. DP Cell Culturing 10 Year Trial Completion. This study is just about ambiguous as it gets in the hair research world. We don’t know the formalities of the trial and if any progress has been made over the years. Nonetheless, it’s very intriguing and could possibly be containing some significant results within it. The trial is studying cultured dermal papillae cells being injected into the scalp to induce hair growth. It’s a study that has been ongoing since at least 2007 and is scheduled to be completed in December 2016. The most significant part of this study is that the methods being utilized here are from the work of Dr. Colin Jahoda, one of the most renowned and longest tenured hair follicle researchers in the world. A real hidden gem is that Dr. Jahoda recently updated his patent for dermal papillae culturing alongside Angela Christiano in August 2015. That could be good news for this study.
6. The Wildcard. The proverbial out-of-nowhere legitimate product that can be brought to market in a very short amount of time. Last year, we had a great example of one in Follicept, which was a potential homerun and could have reached the market in the same year it was announced. Things did not pan out for Follicept the way everyone had hoped, but there is potential that it could still turn out to be a useful product someday.
7. Bag of goodies. Some updates that I expect to see from treatments that show great potential are JAK inhibitors and other Dr. Christiano research, Bimatoprost for scalp, Breezula anti-androgen, Dr. Guillemat’s Stem Cell Transfer, and Theracell.

結果 (中文) 1:

1.Samumed 第二阶段疗效结果。Samumed 可能已经听说的任何头发生长药物的平稳发展。Samumed 最近完成了它的第二阶段试验它的局部头发生长的产品 SM04554 在 2015 年 11 月。在其最新的新闻稿下面引用了博士 Yazici，Samumed，首席医疗官。"第二阶段安全性和有效性数据到目前为止都是非常有前途和支持此程序进入关键的研究。我们正在分析进一步的疗效数据，并计划在即将举行的医学会议提出的临床前和临床研究结果。这里的关键点是疗效数据是很有前途，和足够启动 III 期临床试验有前途，将是最后一次试炼，使商业化的 SM04554。2.资生堂在日本批准审判。月底我预料资生堂将已开始这是首次审理在日本使用 ○-01 对头发的生长。○ 一 01 是名称的技术，已通过 Replicel 使用一个人的自己培养的毛乳头细胞。李盾牌的 Replicel 宣布，资生堂将发起很快对他们的审判。我们也知道 ○-01 日本资生堂的第一次审判的时候，他们将能够为市民提供治疗，虽然他们正在完成 ○-01 以后阶段试验。这意味着世界上的任何人都可以预订飞往日本的航班并获得一些头发生长的针剂。我的家乡。3.宣布审判在墨西哥的 Histogen。我们肯定还不知道是否墨西哥将 Histogen 的官方第一目的地 HSC。如果是，，会很酷，因为墨西哥是很接近我比日本或土耳其。我们知道，盖尔 · 诺顿的 Histogen 一直在评估启动最后研究 HSC 审批的最佳位置。今年，我们将知道该位置和希望很快。4.Follicum 阶段我的审判。在发展现在，Follicum 的 FOL-S-005，我最喜欢的治疗方法之一将开始它的第一次审判，在第一季 2016年的头发生长。Follicum 的产品是外用肽凝胶剂，并表现出相当显著的成果临床前的动物模型。它是我 Follicum 已经被某种"躺"到目前为止在线的意见，我相信这会改变今年。试验将在德国柏林举行。Follicum 曾表示，它将宣布招聘可用性为审判。5. DP Cell Culturing 10 Year Trial Completion. This study is just about ambiguous as it gets in the hair research world. We don’t know the formalities of the trial and if any progress has been made over the years. Nonetheless, it’s very intriguing and could possibly be containing some significant results within it. The trial is studying cultured dermal papillae cells being injected into the scalp to induce hair growth. It’s a study that has been ongoing since at least 2007 and is scheduled to be completed in December 2016. The most significant part of this study is that the methods being utilized here are from the work of Dr. Colin Jahoda, one of the most renowned and longest tenured hair follicle researchers in the world. A real hidden gem is that Dr. Jahoda recently updated his patent for dermal papillae culturing alongside Angela Christiano in August 2015. That could be good news for this study.6. The Wildcard. The proverbial out-of-nowhere legitimate product that can be brought to market in a very short amount of time. Last year, we had a great example of one in Follicept, which was a potential homerun and could have reached the market in the same year it was announced. Things did not pan out for Follicept the way everyone had hoped, but there is potential that it could still turn out to be a useful product someday.7. Bag of goodies. Some updates that I expect to see from treatments that show great potential are JAK inhibitors and other Dr. Christiano research, Bimatoprost for scalp, Breezula anti-androgen, Dr. Guillemat’s Stem Cell Transfer, and Theracell.

結果 (中文) 3:

1。samumed的II期疗效结果。samumed大概有平滑的发展进步的任何毛发生长药物我听说。samumed最近完成的II期临床试验是在2015十一月局部毛发生长的产品sm04554。该研究samumed博士，首席医疗官，是最新的新闻稿下面引用。

“第二阶段的安全性和有效性的数据，到目前为止是非常有前途和支持移动这个程序到关键的研究。我们正在分析疗效数据，并计划在即将到来的医学会议的临床前和临床研究的结果，“”的关键点是，有效数据是非常有前途的，并承诺足以启动III期临床试验，这将使sm04554商品化的最终审判。
2。在日本批准资生堂的审判。到一月底，我预计，资生堂将开始它的头发生长RCH-01使用在日本的第一次审判。RCH-01是技术已通过自己培养的毛乳头细胞RepliCel发达的名字。RepliCel李圆盾已经宣布，资生堂将启动他们的审判很快。我们也知道，当一切都在日本的资生堂RCH-01的首次试验，他们将能够提供治疗的公众在他们完成RCH-01后期试验。这意味着世界上任何一个可以在日本飞行的人都可以获得一些头发生长的注射。呵呵。
3。Histogen宣布在墨西哥试行。我们不知道如果墨西哥将Histogen的HSC官方的第一个目的地。如果是这样，那很酷，因为墨西哥比日本或火鸡更靠近我。我们知道，盖尔诺顿的Histogen已评估为HSC的批准发起最后的研究最好的位置。我们将知道今年的位置，希望很快，4。follicum I期临床试验。我最喜欢的一种治疗发展的现在，follicum的fol-s-005，将开始它的第一个试验的头发生长在第一季度2016。follicum的产品是一种外用肽凝胶，并已在临床前动物模型中表现出了相当显著的效果。我的观点是，follicum就“睡”到目前为止，在线，我相信要改变今年。该试验将在德国柏林举行。follicum此前曾表示，它将公布招聘有效性的试验。
5。DP细胞培养10年试验完成。这项研究是关于暧昧，因为它得到在头发研究世界。我们不知道审判的手续，如果有任何进展，已经取得了多年。尽管如此，这是非常有趣的，并且可能包含一些重要的结果。该试验是研究培养毛乳头细胞被注入到头皮诱导毛发生长。这是一项研究已经持续至少2007，并计划于十二月完成2016。本研究最重要的部分是，利用这里的方法从柯林Jahoda博士的工作，其中最著名和世界上最长的终身毛囊研究。一个真正的隐藏的宝石是期末博士最近更新其专利的真皮乳头培养与安吉拉克里斯2015八月。这可能是好消息，这项研究。通配符。众所周知的不合法的产品，将在很短的时间内市场。去年，我们有一个follicept的一个很好的例子，这是一个潜在的本垒打和可能达到的市场在同年宣布。事情并没有泛出follicept方式每个人都希望，但有潜力，它仍然是一个有用的产品有一天。袋糖果。一些更新，我期待看到的治疗方法，显示出巨大的潜力是JAK抑制剂和其他博士克里斯研究，比马前列素的头皮，breezula抗雄激素，guillemat博士的干细胞移植，并theracell。